Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Guerbet Earnings Release 2012

Apr 18, 2012

1392_iss_2012-04-18_c0f5ec24-3a76-4823-bce2-935b86b4a7d8.pdf

Earnings Release

Open in viewer

Opens in your device viewer

P RESS RELEASE

2012 first-quarter revenue

Villepinte, 18 April 2012

Consolidated Group revenue (IFRS):

In € thousands 2011 2012 Change
Total first quarter…………………… 95,053 96,758 +1.8%

Consolidated revenue by region

In € thousands 2011 2012 Change
European subsidiaries 68,118 70,617 +3.7%
Other markets 26,935 26,141 -2.9%
Total……………………………………… 95,053 96,758 +1.8%

Sales trends in line with new commercial strategy

Growth in sales of 1.8% reflects a deceleration in relation to 2011 though included a timing effect for operations outside Europe. Adjusting for this effect, growth would be 5% overall and 8.5% for other markets.

As announced when 2011 results were released, the top priority today is optimising the margin by focussing on profitable countries and customers, even if this means slowing the pace of sales.

In Europe, sales revenue for Dotarem (+4.8%) in consequence outpaced volume sales (+4.6%). This trend was even more pronounced for Xenetix with a decline in volumes of 5.1% (reduced sales to low-margin distributors) compared with only 1.1% for sales revenue.

In the other markets, Dotarem registered a 11.2% decline in volume sales compared with 5.1% for sales revenue. Xenetix in contrast has maintained strong growth for both volumes (+26.4%) and sales revenue (+10.3%), driven by significant deliveries to Asia (South Korea and China) and Mexico.

Contact: Administrative and Finance Department Tel.: +33 (0)1 45 91 50 69